S-101479

An investigational antiviral drug

S-101479 is an investigational antiviral drug that has been studied for its potential use in treating viral infections. It is a nucleoside analog, which means it mimics the building blocks of viral RNA or DNA, thereby interfering with the replication process of viruses.

Mechanism of Action

S-101479 works by inhibiting viral RNA polymerase, an enzyme crucial for the replication of viral RNA. By incorporating itself into the viral RNA chain, S-101479 causes premature chain termination, effectively halting the replication of the virus. This mechanism is similar to other nucleoside analogs used in antiviral therapy, such as Remdesivir and Favipiravir.

Pharmacokinetics

The pharmacokinetics of S-101479 have been studied in preclinical models. The drug is administered orally and is rapidly absorbed into the bloodstream. It undergoes extensive metabolism in the liver, where it is converted into its active triphosphate form. The elimination half-life of S-101479 is approximately 4 to 6 hours, and it is primarily excreted through the kidneys.

Clinical Trials

S-101479 has undergone several phases of clinical trials to evaluate its safety and efficacy. In Phase I trials, the drug was well-tolerated with no serious adverse effects reported. Phase II trials demonstrated a reduction in viral load in patients with acute viral infections. Further studies are ongoing to assess its effectiveness against specific viruses such as Influenza and SARS-CoV-2.

Potential Applications

Due to its broad-spectrum antiviral activity, S-101479 is being investigated for use against a variety of viral pathogens. It holds promise for treating infections caused by RNA viruses, including influenza viruses, coronaviruses, and other emerging viral threats.

Safety and Side Effects

In clinical studies, S-101479 has been generally well-tolerated. Common side effects include mild gastrointestinal disturbances, headache, and fatigue. No significant drug-drug interactions have been observed, making it a potential candidate for combination therapy with other antiviral agents.

Research and Development

S-101479 is currently under development by a pharmaceutical company specializing in antiviral therapies. Ongoing research aims to optimize its formulation, improve its pharmacokinetic profile, and expand its therapeutic indications.

Also see

• Antiviral drug
• Nucleoside analog
• RNA polymerase inhibitor
• Viral replication

Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B Inhibitors (Polymerase inhibitors)

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus

• infections (HSV), CMV, others

Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir